查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2065241

精準腫瘤診斷市場預測至2034年－按產品類型、技術、生物標記類型、檢體類型、癌症類型、最終用戶和地區分類的全球分析

Precision Oncology Diagnostics Market Forecasts to 2034 - Global Analysis By Product Type, Technology, Biomarker Type, Sample Type, Cancer Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球精準腫瘤診斷市場預計將在 2026 年達到 83 億美元，到 2034 年達到 286 億美元，在預測期內複合年成長率為 16.7%。

精準腫瘤診斷是指利用先進的分子和基因組檢測技術，從基因、蛋白質體學和表觀遺傳學層面闡明個別腫瘤的生物學特徵。這使得腫瘤科醫師能夠為每位患者選擇最有效的臨床治療方法。該領域整合了新一代定序、液態生物檢體、伴隨診斷和人工智慧驅動的生物資訊學，以實現全面的腫瘤分析和生物標記識別。

由於伴隨診斷的要求，抗癌藥物獲準數量激增。

包括FDA和EMA在內的監管機構正日益強制要求伴隨診斷試劑的共同開發和聯合核准，作為標靶治療上市的必要條件，從而在藥物上市和診斷試劑的應用之間建立結構性連結。隨著基於生物標記的癌症治療方案在非小細胞肺癌、乳癌和骨髓惡性腫瘤等適應症領域不斷擴展，對檢驗的伴隨診斷試劑的需求也相應成長。這個法律規範要求在開始治療前對每位獲準的標靶治療患者進行經驗證的篩檢檢驗，從而確保診斷市場的持續成長。

檢測成本高昂，而醫療系統資源有限，檢測機會卻十分有限。

全面的基因組分析和基於新一代定序（NGS）的精準診斷每次檢測費用都相當昂貴，往往超出醫保報銷範圍，尤其是在中低收入國家以及醫保報銷標準較為保守的地區。分子腫瘤學檢測所需的專業基礎設施、訓練有素的檢查室人員以及生物資訊學專業知識進一步阻礙了其在大型大學醫院以外的普及。複雜的基因組分析耗時較長，可能延誤時間緊迫的治療決策。這些醫療資源分配不均導致精準腫瘤學的益處主要集中在醫療資源較為豐富的患者群體中，從而限制了市場充分發揮其成長潛力。

液態生物檢體的商業化和多癌種早期檢測項目

能夠以微創方式檢測循環腫瘤DNA、RNA和蛋白質的液態生物檢體技術，展現出突破性的商業性機會。該技術無需重複組織取樣，即可實現腫瘤的即時監測、治療反應評估和抗藥性檢測。多癌種早期檢測組合的出現，僅需一份血液樣本即可識別數十種癌症類型的訊號，催生了一個全新的篩檢市場。隨著臨床檢驗數據的累積和液態生物檢體適應症的醫保報銷範圍擴大，這些平台有望推動顯著的收入成長，並從根本上改變癌症的檢測和治療方式。

生物資訊分析的複雜性和變異分類的不確定性。

下一代定序（NGS）在腫瘤診斷中的臨床效用取決於準確的生物資訊分析和突變分類，而這一環節存在顯著的檢查室間差異，且科學共識不斷變化。意義不明的突變會造成臨床上的歧義，使治療決策複雜化，並可能削弱臨床醫師對分子檢測結果的信心。隨著基因組資料庫的擴充，發現的基因突變數量迅速增加，因此需要不斷更新解讀演算法和臨床指引。如果無法維持分析的準確性和透明的報告標準，不僅會使診斷機構面臨嚴格的監管審查，還會限制全面基因組分析在常規腫瘤診療中的廣泛應用。

新冠疫情的影響

新冠疫情導致檢查室關閉、腫瘤治療延誤以及分子檢測能力向感染疾病領域的重新分配，暫時擾亂了精準腫瘤診斷。然而，這場危機加速了檢查室數位化進程，提升了遠距病理能力，同時也凸顯了液態生物檢體對不願前往醫療機構的患者而言具有的效率優勢。疫情後的復甦勢頭強勁，腫瘤計畫優先解決檢測瓶頸問題，並增加對高擴展性分子診斷平台的投資。最終，疫情再次印證了整合精準診斷在腫瘤治療路徑中的策略價值。

預計在預測期內，伴隨診斷領域將佔據最大的市場佔有率。

在預測期內，伴隨診斷領域預計將佔據最大的市場佔有率，這主要得益於監管機構要求將標靶治療的核准與關鍵腫瘤適應症中已驗證的患者檢驗檢測掛鉤。針對乳癌、肺癌和大腸癌的重磅療法，伴隨診斷持續推動腫瘤臨床工作流程中常規檢測的顯著需求。不斷擴充的標靶治療產品線將持續為新型伴隨診斷的開發提供機遇，而基於生物標記分層的藥物核准數量的增加預計將使該領域在整個預測期內保持市場領先地位。

在預測期內，液態生物檢體檢測領域預計將呈現最高的複合年成長率。

在預測期內，液態生物檢體檢測領域預計將呈現最高的成長率，這反映了在報銷核准擴大、臨床效用數據令人信服以及平台靈敏度提升方面持續投入巨資的推動下，臨床應用加速發展。透過連續採集血液樣本來監測治療反應、檢測微量殘存疾病以及識別新出現的抗藥性突變，代表癌症管理模式的模式轉移。針對治療監測、早期檢測和復發監測等新的液態生物檢體適應症的法規核准，正在大幅擴大目標市場。

市佔率最大的地區

在整個預測期內，北美地區預計將保持最大的市場佔有率。這主要得益於該地區較高的人均癌症發病率、分子診斷檢測的廣泛保險覆蓋範圍，以及由基因組學公司、大學附屬癌症中心和生物製藥開發公司組成的密集生態系統，這些公司都在積極尋求伴隨診斷方面的合作。美國在已獲已通過核准的伴隨診斷檢測和全面基因組分析的應用方面處於全球領先地位，這得益於聯邦醫療保險（Medicare）的保險覆蓋政策，該政策逐步擴大了晚期癌症患者分子檢測的保險覆蓋範圍。

複合年成長率最高的地區

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於癌症發病率的快速成長、患者意識的提高以及中國、印度、日本和韓國政府對基因組醫療基礎設施的投入。各國癌症基因組學計畫和精準醫療舉措正在建構分子診斷能力，同時也正在加深臨床醫生對基於生物標記的治療選擇的理解。 NGS測序成本的降低和本地基因組服務供應商的建立，使得該地區多元化的醫療保健市場能夠廣泛獲得全面的腫瘤基因分析。

免費客製化服務

所有購買此報告的客戶均可享受以下免費自訂選項之一。

  • 企業概況
    • 對其他市場參與企業（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 透過產品系列、地域覆蓋和策略聯盟對標領先企業。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 成長機會和重點投資領域
  • 工業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球精準腫瘤診斷市場：依產品類型分類

  • 伴隨診斷
  • 綜合基因組分析（CGP）
  • 液態生物檢體檢測
  • 單生物標記檢測
  • 分子診斷測試
  • 次世代定序 (NGS) 檢測
  • 其他

第6章：全球精準腫瘤診斷市場：依技術分類

  • 下一代定序（NGS）
  • 聚合酵素鏈鎖反應（PCR）
  • 免疫組織化學（IHC）
  • 原位雜合反應（ISH）
  • 微陣列技術
  • 質譜分析
  • 人工智慧（AI）和生物資訊學

第7章 全球精準腫瘤診斷市場：依生物標記類型分類

  • 基因生物標記
  • 蛋白質生物標記
  • 表觀遺傳生物標記
  • 代謝體學物標誌物
  • 多組體學物標誌物

第8章：全球精準腫瘤診斷市場：依檢體類型分類

  • 組織切片檢查
  • 液態生物檢體
  • 血液檢體
  • 尿液檢體
  • 唾液檢體
  • 其他檢體類型

第9章 全球精準腫瘤診斷市場：依癌症類型分類

  • 乳癌
  • 肺癌
  • 結腸癌
  • 攝護腺癌
  • 子宮頸癌
  • 血癌
  • 卵巢癌
  • 胰臟癌

第10章 全球精準腫瘤診斷市場：依最終用戶分類

  • 醫院
  • 診斷實驗室
  • 癌症研究機構
  • 學術和研究機構
  • 製藥和生物技術公司
  • 專科診所
  • 其他

第11章 全球精準腫瘤診斷市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 其他
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲地區

第12章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第13章：產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟、合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第14章：公司簡介

  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • QIAGEN NV
  • Guardant Health, Inc.
  • Agilent Technologies, Inc.
  • Myriad Genetics, Inc.
  • Exact Sciences Corporation
  • Bio-Rad Laboratories, Inc.
  • Tempus AI, Inc.
  • Caris Life Sciences
  • Natera, Inc.
  • SOPHiA GENETICS SA
  • bioMerieux SA
  • Abbott Laboratories
Product Code: SMRC36752

According to Stratistics MRC, the Global Precision Oncology Diagnostics Market is accounted for $8.3 billion in 2026 and is expected to reach $28.6 billion by 2034, growing at a CAGR of 16.7% during the forecast period. Precision Oncology Diagnostics encompasses advanced molecular and genomic testing technologies designed to characterize individual tumor biology at the genetic, proteomic, and epigenetic levels, enabling oncologists to select therapies with the highest probability of clinical efficacy for each patient. This discipline integrates next-generation sequencing, liquid biopsy, companion diagnostics, and AI-powered bioinformatics to deliver comprehensive tumor profiling and biomarker identification.

Market Dynamics:

Driver:

Surge in oncology drug approvals tied to companion diagnostic requirements

Regulatory agencies including the FDA and EMA have increasingly mandated companion diagnostic co-development and co-approval as a condition for targeted therapy market authorization, creating a structural link between drug launches and diagnostic adoption. As the pipeline of biomarker-driven oncology therapies expands across indications including non-small cell lung cancer, breast cancer, and hematologic malignancies, the demand for validated companion diagnostic assays grows proportionally. This regulatory architecture ensures sustained diagnostic market expansion as each approved targeted therapy generates a corresponding requirement for validated patient selection testing before treatment initiation.

Restraint:

High test costs and limited access in resource-constrained healthcare systems

Comprehensive genomic profiling and NGS-based precision diagnostics carry significant per-test costs that frequently exceed reimbursement thresholds, particularly in lower-middle income countries and payer systems applying conservative coverage criteria. The specialized infrastructure, trained laboratory personnel, and bioinformatics expertise required for molecular oncology testing place additional barriers on adoption outside major academic medical centers. Turnaround times for complex genomic analyses can delay time-sensitive treatment decisions. These access inequities mean that precision oncology benefits remain disproportionately concentrated among patients in well-resourced health systems, limiting the market's full growth potential.

Opportunity:

Liquid biopsy commercialization and multi-cancer early detection programs

Liquid biopsy technologies enabling minimally invasive detection of circulating tumor DNA, RNA, and proteins represent a transformative commercial opportunity, allowing real-time tumor monitoring, therapy response assessment, and treatment resistance detection without repeated tissue sampling. The emergence of multi-cancer early detection panels capable of identifying signal across dozens of cancer types from a single blood draw is creating an entirely new screening market segment. As clinical validation data matures and reimbursement pathways for liquid biopsy indications expand, these platforms are positioned to generate substantial revenue growth while fundamentally reshaping how cancers are detected and managed.

Threat:

Bioinformatics interpretation complexity and variant classification uncertainty

The clinical utility of NGS-based oncology diagnostics is contingent upon accurate bioinformatics analysis and variant classification a domain characterized by significant interlaboratory variability and evolving scientific consensus. Variants of uncertain significance generate clinical ambiguity that complicates treatment decision-making and can undermine clinician confidence in molecular testing results. The rapid proliferation of genetic variants discovered through expanding genomic databases requires continuous updates to interpretation algorithms and clinical guidelines. Failure to maintain analytical accuracy and transparent reporting standards exposes diagnostic providers to regulatory scrutiny and limits the uptake of comprehensive genomic profiling in routine oncology practice.

Covid-19 Impact:

The COVID-19 pandemic temporarily disrupted precision oncology diagnostics through laboratory closures, oncology care deferrals, and reallocation of molecular testing capacity toward infectious disease applications. However, the crisis accelerated laboratory digitalization and remote pathology capabilities while highlighting the efficiency advantages of liquid biopsy for patients hesitant to visit medical facilities. Post-pandemic recovery has been robust, with oncology programs prioritizing backlog clearance and increasing investment in scalable molecular diagnostic platforms. The pandemic ultimately reinforced the strategic value of integrated precision diagnostics within oncology care pathways.

The Companion Diagnostics segment is expected to be the largest during the forecast period

The companion diagnostics segment is expected to account for the largest market share during the forecast period, driven by regulatory mandates linking targeted therapy approvals to validated patient selection assays across major oncology indications. Companion diagnostics for established blockbuster therapies in breast, lung, and colorectal cancer continue to generate substantial recurring test volumes within oncology clinical workflows. The expanding targeted therapy pipeline ensures continuous new companion diagnostic development opportunities, sustaining this segment's market leadership through increasing biomarker-stratified drug approvals over the forecast period.

The Liquid Biopsy Assays segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Liquid Biopsy Assays segment is predicted to witness the highest growth rate, reflecting accelerating clinical adoption driven by expanding reimbursement approvals, compelling clinical utility data, and significant ongoing investment in platform sensitivity improvements. The ability to monitor treatment response, detect minimal residual disease, and identify emerging resistance mutations through serial blood sampling represents a paradigm shift in cancer management. Regulatory approvals for new liquid biopsy indications across therapy monitoring, early detection, and recurrence surveillance are expanding the addressable market considerably.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by high per-capita cancer incidence, strong insurance coverage for molecular diagnostic testing, and a dense ecosystem of genomics companies, academic cancer centers, and biopharmaceutical developers pursuing companion diagnostic partnerships. The United States leads globally in approved companion diagnostic assays and comprehensive genomic profiling adoption, supported by Medicare coverage policies that have progressively expanded molecular testing reimbursement for advanced cancer patients.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, propelled by rapidly expanding cancer incidence, growing patient awareness, and government investments in genomic medicine infrastructure across China, India, Japan, and South Korea. National cancer genome projects and precision medicine initiatives are building molecular diagnostic capabilities while increasing clinician familiarity with biomarker-driven treatment selection. Decreasing NGS sequencing costs and the establishment of local genomics service providers are democratizing access to comprehensive tumor profiling across the region's diverse healthcare markets.

Key players in the market

Some of the key players in Precision Oncology Diagnostics Market include F. Hoffmann-La Roche Ltd, Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Guardant Health, Inc., Agilent Technologies, Inc., Myriad Genetics, Inc., Exact Sciences Corporation, Bio-Rad Laboratories, Inc., Tempus AI, Inc., Caris Life Sciences, Natera, Inc., SOPHIA GENETICS SA, bioMerieux SA, and Abbott Laboratories.

Key Developments:

In March 2026, Guardant Health received FDA approval for an expanded indication of its liquid biopsy platform for therapy selection in advanced colorectal cancer, enabling comprehensive genomic profiling from a standard blood draw and significantly broadening reimbursement access for patients ineligible for repeat tissue biopsy.

In February 2026, Illumina announced a collaboration with a leading biopharmaceutical company to co-develop a next-generation NGS-based companion diagnostic panel for a novel pan-tumor targeted therapy, advancing an integrated precision oncology approach linking biomarker testing directly to matched treatment selection at diagnosis.

Product Types Covered:

  • Companion Diagnostics
  • Comprehensive Genomic Profiling (CGP)
  • Liquid Biopsy Assays
  • Single Biomarker Tests
  • Molecular Diagnostic Tests
  • Next-Generation Sequencing (NGS)-Based Tests
  • Other Product Types

Technologies Covered:

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • In Situ Hybridization (ISH)
  • Microarray Technology
  • Mass Spectrometry
  • Artificial Intelligence & Bioinformatics

Biomarker Types Covered:

  • Genetic Biomarkers
  • Protein Biomarkers
  • Epigenetic Biomarkers
  • Metabolomic Biomarkers
  • Multi-Omics Biomarkers

Sample Types Covered:

  • Tissue Biopsy
  • Liquid Biopsy
  • Blood Samples
  • Urine Samples
  • Saliva Samples
  • Other Sample Types

Cancer Types Covered:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Cervical Cancer
  • Hematologic Cancers
  • Ovarian Cancer
  • Pancreatic Cancer

End Users Covered:

  • Hospitals
  • Diagnostic Laboratories
  • Cancer Research Institutes
  • Academic & Research Centers
  • Pharmaceutical & Biotechnology Companies
  • Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Precision Oncology Diagnostics Market, By Product Type

  • 5.1 Companion Diagnostics
  • 5.2 Comprehensive Genomic Profiling (CGP)
  • 5.3 Liquid Biopsy Assays
  • 5.4 Single Biomarker Tests
  • 5.5 Molecular Diagnostic Tests
  • 5.6 Next-Generation Sequencing (NGS)-Based Tests
  • 5.7 Other Product Types

6 Global Precision Oncology Diagnostics Market, By Technology

  • 6.1 Next-Generation Sequencing (NGS)
  • 6.2 Polymerase Chain Reaction (PCR)
  • 6.3 Immunohistochemistry (IHC)
  • 6.4 In Situ Hybridization (ISH)
  • 6.5 Microarray Technology
  • 6.6 Mass Spectrometry
  • 6.7 Artificial Intelligence & Bioinformatics

7 Global Precision Oncology Diagnostics Market, By Biomarker Type

  • 7.1 Genetic Biomarkers
  • 7.2 Protein Biomarkers
  • 7.3 Epigenetic Biomarkers
  • 7.4 Metabolomic Biomarkers
  • 7.5 Multi-Omics Biomarkers

8 Global Precision Oncology Diagnostics Market, By Sample Type

  • 8.1 Tissue Biopsy
  • 8.2 Liquid Biopsy
  • 8.3 Blood Samples
  • 8.4 Urine Samples
  • 8.5 Saliva Samples
  • 8.6 Other Sample Types

9 Global Precision Oncology Diagnostics Market, By Cancer Type

  • 9.1 Breast Cancer
  • 9.2 Lung Cancer
  • 9.3 Colorectal Cancer
  • 9.4 Prostate Cancer
  • 9.5 Cervical Cancer
  • 9.6 Hematologic Cancers
  • 9.7 Ovarian Cancer
  • 9.8 Pancreatic Cancer

10 Global Precision Oncology Diagnostics Market, By End User

  • 10.1 Hospitals
  • 10.2 Diagnostic Laboratories
  • 10.3 Cancer Research Institutes
  • 10.4 Academic & Research Centers
  • 10.5 Pharmaceutical & Biotechnology Companies
  • 10.6 Specialty Clinics
  • 10.7 Other End Users

11 Global Precision Oncology Diagnostics Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 F. Hoffmann-La Roche Ltd
  • 14.2 Illumina, Inc.
  • 14.3 Thermo Fisher Scientific Inc.
  • 14.4 QIAGEN N.V.
  • 14.5 Guardant Health, Inc.
  • 14.6 Agilent Technologies, Inc.
  • 14.7 Myriad Genetics, Inc.
  • 14.8 Exact Sciences Corporation
  • 14.9 Bio-Rad Laboratories, Inc.
  • 14.10 Tempus AI, Inc.
  • 14.11 Caris Life Sciences
  • 14.12 Natera, Inc.
  • 14.13 SOPHiA GENETICS SA
  • 14.14 bioMerieux SA
  • 14.15 Abbott Laboratories

List of Tables

  • Table 1 Global Precision Oncology Diagnostics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Precision Oncology Diagnostics Market Outlook, By Product Type (2023-2034) ($MN)
  • Table 3 Global Precision Oncology Diagnostics Market Outlook, By Companion Diagnostics (2023-2034) ($MN)
  • Table 4 Global Precision Oncology Diagnostics Market Outlook, By Comprehensive Genomic Profiling (CGP) (2023-2034) ($MN)
  • Table 5 Global Precision Oncology Diagnostics Market Outlook, By Liquid Biopsy Assays (2023-2034) ($MN)
  • Table 6 Global Precision Oncology Diagnostics Market Outlook, By Single Biomarker Tests (2023-2034) ($MN)
  • Table 7 Global Precision Oncology Diagnostics Market Outlook, By Molecular Diagnostic Tests (2023-2034) ($MN)
  • Table 8 Global Precision Oncology Diagnostics Market Outlook, By Next-Generation Sequencing (NGS)-Based Tests (2023-2034) ($MN)
  • Table 9 Global Precision Oncology Diagnostics Market Outlook, By Other Product Types (2023-2034) ($MN)
  • Table 10 Global Precision Oncology Diagnostics Market Outlook, By Technology (2023-2034) ($MN)
  • Table 11 Global Precision Oncology Diagnostics Market Outlook, By Next-Generation Sequencing (NGS) (2023-2034) ($MN)
  • Table 12 Global Precision Oncology Diagnostics Market Outlook, By Polymerase Chain Reaction (PCR) (2023-2034) ($MN)
  • Table 13 Global Precision Oncology Diagnostics Market Outlook, By Immunohistochemistry (IHC) (2023-2034) ($MN)
  • Table 14 Global Precision Oncology Diagnostics Market Outlook, By In Situ Hybridization (ISH) (2023-2034) ($MN)
  • Table 15 Global Precision Oncology Diagnostics Market Outlook, By Microarray Technology (2023-2034) ($MN)
  • Table 16 Global Precision Oncology Diagnostics Market Outlook, By Mass Spectrometry (2023-2034) ($MN)
  • Table 17 Global Precision Oncology Diagnostics Market Outlook, By Artificial Intelligence & Bioinformatics (2023-2034) ($MN)
  • Table 18 Global Precision Oncology Diagnostics Market Outlook, By Biomarker Type (2023-2034) ($MN)
  • Table 19 Global Precision Oncology Diagnostics Market Outlook, By Genetic Biomarkers (2023-2034) ($MN)
  • Table 20 Global Precision Oncology Diagnostics Market Outlook, By Protein Biomarkers (2023-2034) ($MN)
  • Table 21 Global Precision Oncology Diagnostics Market Outlook, By Epigenetic Biomarkers (2023-2034) ($MN)
  • Table 22 Global Precision Oncology Diagnostics Market Outlook, By Metabolomic Biomarkers (2023-2034) ($MN)
  • Table 23 Global Precision Oncology Diagnostics Market Outlook, By Multi-Omics Biomarkers (2023-2034) ($MN)
  • Table 24 Global Precision Oncology Diagnostics Market Outlook, By Sample Type (2023-2034) ($MN)
  • Table 25 Global Precision Oncology Diagnostics Market Outlook, By Tissue Biopsy (2023-2034) ($MN)
  • Table 26 Global Precision Oncology Diagnostics Market Outlook, By Liquid Biopsy (2023-2034) ($MN)
  • Table 27 Global Precision Oncology Diagnostics Market Outlook, By Blood Samples (2023-2034) ($MN)
  • Table 28 Global Precision Oncology Diagnostics Market Outlook, By Urine Samples (2023-2034) ($MN)
  • Table 29 Global Precision Oncology Diagnostics Market Outlook, By Saliva Samples (2023-2034) ($MN)
  • Table 30 Global Precision Oncology Diagnostics Market Outlook, By Other Sample Types (2023-2034) ($MN)
  • Table 31 Global Precision Oncology Diagnostics Market Outlook, By Cancer Type (2023-2034) ($MN)
  • Table 32 Global Precision Oncology Diagnostics Market Outlook, By Breast Cancer (2023-2034) ($MN)
  • Table 33 Global Precision Oncology Diagnostics Market Outlook, By Lung Cancer (2023-2034) ($MN)
  • Table 34 Global Precision Oncology Diagnostics Market Outlook, By Colorectal Cancer (2023-2034) ($MN)
  • Table 35 Global Precision Oncology Diagnostics Market Outlook, By Prostate Cancer (2023-2034) ($MN)
  • Table 36 Global Precision Oncology Diagnostics Market Outlook, By Cervical Cancer (2023-2034) ($MN)
  • Table 37 Global Precision Oncology Diagnostics Market Outlook, By Hematologic Cancers (2023-2034) ($MN)
  • Table 38 Global Precision Oncology Diagnostics Market Outlook, By Ovarian Cancer (2023-2034) ($MN)
  • Table 39 Global Precision Oncology Diagnostics Market Outlook, By Pancreatic Cancer (2023-2034) ($MN)
  • Table 40 Global Precision Oncology Diagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 41 Global Precision Oncology Diagnostics Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 42 Global Precision Oncology Diagnostics Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 43 Global Precision Oncology Diagnostics Market Outlook, By Cancer Research Institutes (2023-2034) ($MN)
  • Table 44 Global Precision Oncology Diagnostics Market Outlook, By Academic & Research Centers (2023-2034) ($MN)
  • Table 45 Global Precision Oncology Diagnostics Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 46 Global Precision Oncology Diagnostics Market Outlook, By Specialty Clinics (2023-2034) ($MN)
  • Table 47 Global Precision Oncology Diagnostics Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.